This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Fujian Haixi Pharmaceuticals Co., Ltd. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Jianjia Zheng: Innovator in Kinase Inhibitor Compounds
Introduction
Jianjia Zheng is a notable inventor based in Fujian, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of kinase inhibitors. His work is characterized by a focus on heteroaryl compounds that have potential therapeutic applications.
Latest Patents
Jianjia Zheng holds a patent for "Heteroaryl compounds as kinase inhibitor." This patent describes compounds of formula (I) that exhibit activity on a receptor protein tyrosine kinase. The patent also includes solvates, hydrates, tautomers, or pharmaceutically acceptable salts of these compounds.
Career Highlights
Zheng is currently associated with Fujian Haixi Pharmaceuticals Co., Ltd., where he continues to innovate in the pharmaceutical sector. His expertise in the development of kinase inhibitors has positioned him as a valuable asset in his field.
Collaborations
He has collaborated with notable coworkers such as Yan Feng and Ruyong Wang, contributing to various projects that enhance the understanding and application of kinase inhibitors.
Conclusion
Jianjia Zheng's work in the development of heteroaryl compounds as kinase inhibitors showcases his commitment to advancing pharmaceutical science. His contributions are expected to have a lasting impact on the industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile